Resmetirom and metabolic dysfunction-associated steatohepatitis: perspectives on multidisciplinary management from global healthcare professionals
Resmetirom and metabolic dysfunction-associated steatohepatitis: perspectives on multidisciplinary management from global healthcare professionals
Purpose of Review: the approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed.
Recent Findings: resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted.
Summary: MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
Au, Kahei
8d1339c9-a13a-4d09-b0c2-f3a36cedd25d
Zheng, Ming-Hua
67523368-2f19-4836-99b2-986093cb3707
Lee, Wei-Jei
db61d76e-d160-49bc-9267-9194a52b6ce5
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Global Obesity Collaborative
Au, Kahei
8d1339c9-a13a-4d09-b0c2-f3a36cedd25d
Zheng, Ming-Hua
67523368-2f19-4836-99b2-986093cb3707
Lee, Wei-Jei
db61d76e-d160-49bc-9267-9194a52b6ce5
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Au, Kahei, Zheng, Ming-Hua and Lee, Wei-Jei
,
Global Obesity Collaborative
(2024)
Resmetirom and metabolic dysfunction-associated steatohepatitis: perspectives on multidisciplinary management from global healthcare professionals.
Current Obesity Reports.
(doi:10.1007/s13679-024-00582-z).
Abstract
Purpose of Review: the approval of resmetirom brings great hope to patients with metabolic dysfunction-associated steatohepatitis (MASH). The purpose of this review is to explore its impact on the global health environment. The implementation of multidisciplinary management MASH is proposed.
Recent Findings: resmetirom has benefits in the treatment of MASH, and its safety and effectiveness have been studied. The adverse events (AEs) need to be noticed. To improve patient outcomes, a multimodal approach with medication such as resmetirom, combined with metabolic and bariatric surgery (MBS) and lifestyle interventions can be conducted.
Summary: MASH, a liver disease linked with obesity, is a challenging global healthcare burden compounded by the absence of any approved pharmacotherapy. The recent conditional approval by the Food and Drug Administration (FDA) in the United States of resmetirom, an oral, liver-directed, thyroid hormone receptor beta-selective agonist, marks a significant milestone, offering a treatment option for adults with non-cirrhotic MASH and who have moderate to advanced liver fibrosis. This narrative review discusses the efficacy and safety of resmetirom and its role in the therapeutic landscape of MASH treatment. Despite the promising hepatoprotective effect of resmetirom on histological liver endpoints, its use need further research, particularly regarding ethnic differences, effectiveness and cost-effectiveness, production scalability, social acceptance and accessibility. In addition, integrating resmetirom with other multidisciplinary therapeutic approaches, including lifestyle changes and MBS, might further improve clinical liver-related and cardiometabolic outcomes of individuals with MASH. This review highlights the importance of a comprehensive treatment strategy, supporting continued innovation and collaborative research to refine treatment guidelines and consensus for managing MASH, thereby improving clinical patient outcomes in the growing global epidemic of MASH. Studies done to date have been relatively short and ongoing, the course of the disease is highly variable, the conditions of various patients vary, and given this complex clinical phenotype, it may take many years of clinical trials to show long-term benefits.
Text
Manuscript clean 2024-07-21
- Accepted Manuscript
Restricted to Repository staff only until 1 July 2025.
Request a copy
More information
Accepted/In Press date: 25 July 2024
e-pub ahead of print date: 7 August 2024
Identifiers
Local EPrints ID: 493393
URI: http://eprints.soton.ac.uk/id/eprint/493393
PURE UUID: d3a269ef-0de8-4ac2-9862-c514b72b8c37
Catalogue record
Date deposited: 02 Sep 2024 16:44
Last modified: 07 Sep 2024 01:36
Export record
Altmetrics
Contributors
Author:
Kahei Au
Author:
Ming-Hua Zheng
Author:
Wei-Jei Lee
Corporate Author: Global Obesity Collaborative
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics